https://ipharmag.com/article/moderna-merck-mrna-melanoma-vaccine-phase-3-interpath iPharmag en 2026-08-19T12:18:48+00:00 Moderna and Merck’s mRNA Cancer Vaccine Succeeds in Landmark Phase 3 Melanoma Trial https://ipharmag.com/article/faeth-piktor-paclitaxel-fda-fast-track-endometrial-cancer iPharmag en 2026-08-19T12:18:48+00:00 FDA Grants Fast Track to Faeth’s Metabolic Cancer Combo for Advanced Endometrial Cancer https://ipharmag.com/article/blood-pressure-ccb-kidney-risk-type-2-diabetes iPharmag en 2026-08-19T12:18:48+00:00 A Common Blood-Pressure Drug Class Is Linked to Higher Kidney Risk in Type 2 Diabetes, Study Finds https://ipharmag.com/article/astrazeneca-tagrisso-saffron-egfr-met-lung-cancer iPharmag en 2026-08-19T12:18:48+00:00 AstraZeneca’s Tagrisso Combo Extends Survival in Hard-to-Treat Lung Cancer https://ipharmag.com/article/amylyx-avexitide-glp1-blocker-post-bariatric-hypoglycemia iPharmag en 2026-08-19T12:18:48+00:00 Amylyx’s Bet on a GLP-1 ‘Blocker’ Pays Off in Post-Surgery Low Blood Sugar https://ipharmag.com/article/slate-fulcrum-reverse-merger-migraine-pacap iPharmag en 2026-08-18T03:43:14+00:00 Fulcrum Pivots to Migraine, Merging With Slate to Chase a New Drug Target https://ipharmag.com/article/malaria-chemovaccination-mosquito-bites-immunity iPharmag en 2026-08-18T03:43:14+00:00 Turning Mosquito Bites Into Vaccinations: A New Malaria Strategy Protects Mice https://ipharmag.com/article/eyepoint-durayvu-wet-amd-trial-miss iPharmag en 2026-08-18T03:43:14+00:00 EyePoint Shares Crater 70% After Eye Drug Misses in Pivotal Wet AMD Trial https://ipharmag.com/article/argenx-vyvgart-myositis-phase-3-alkivia iPharmag en 2026-08-18T03:43:14+00:00 Argenx’s Vyvgart Succeeds in Myositis Trial, Opening a New Front for the Blockbuster https://ipharmag.com/article/albumin-fused-antibodies-reduce-fetal-drug-exposure iPharmag en 2026-08-18T03:43:14+00:00 A Redesigned Antibody Could Let Pregnant Patients Take Biologic Drugs More Safely